We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Intralesional Antimony for Bolivian Cutaneous Leishmaniasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01300975
Recruitment Status : Completed
First Posted : February 23, 2011
Last Update Posted : July 6, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
Intralesional injection of antimony has been used for L major from Iran with a modest cure rate [56%: Asilian 2004]. However, this therapeutic approach has been used for L braziliensis from Brazil, with an attractive cure rate after 3 months of 80% [Oliveira-Neto 1997]. Because intralesional Sb injections is the local therapy with the best reported cure rate for South American L braziliensis disease, the species that causes disease in Bolivia, this pilot study of local therapy for bolivian L braziliensis disease will evaluate intralesional Sb therapy.

Condition or disease Intervention/treatment Phase
Leishmaniasis Cutaneous Leishmaniasis Drug: pentavalent antimony Procedure: cryotherapy Drug: placebo cream Phase 2

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Short Course of Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
Study Start Date : January 2011
Primary Completion Date : July 2012
Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leishmaniasis
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Intralesional antimony
3 intralesional injections of antimony at D1, D3 and D7
Drug: pentavalent antimony
3 intralesional injections of antimony at D1, D3 and D7
Active Comparator: Cryotherapy
Liquid nitrogen until freezing at DF1 and D14
Procedure: cryotherapy
Frozing of lesions with liquid nitrogen ad D1 and D14
Placebo Comparator: Topical cream
topical treatment 3 times a day during 21 days with an emollient cream
Drug: placebo cream
topical emollient crean 3 times a day during 21 days

Outcome Measures

Primary Outcome Measures :
  1. Complete clinical cure [ Time Frame: six months ]
    100% epithelization, complete resolution of swelling and infiltration

Secondary Outcome Measures :
  1. EKG changes associated with IL Sb, local reactions to cream and Cryo [ Time Frame: six months ]
    Ealuation of clinical findings and changes in OKG, lipase and SGOT in patients receiving intralesional antimony

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Gender: Male or female
  • Age: >12 yrs of age
  • Clinicla presentation: 1-2 ulcerative lesions, each < 30 mm in largest diameter, and with a total lesion area <900 mm2.
  • Parasitological confirmation of the lesion will be made by visualization or culture of leishmania from the biopsy or aspirate of the lesion.


  • Previous treatment for leishmaniasis: therapy with Sb, pentamidine, amphotericin B, miltefosine, imidazoles or allopurinol in the last 3 months
  • Concomitant diseases by history that would be likely in the PI's opinion to interact, either positively or negatively, with IL Sb treatment.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01300975

CUNETROP - Universidad Mayor de San Simon
Cochabamba, CB, Bolivia
Hospital Dermatologico de Jorochito
Jorochito, SC, Bolivia
Sponsors and Collaborators
Fundacion Nacional de Dermatologia
The Alfred Berman Foundation for Medical Research
Universidad Mayor de San Simón
Hospital Dermatológico de Jorochito
Proyecto OSCAR
Study Chair: Jonathan Berman, MD PhD ABF
Study Director: Jaime Soto, MD Fundacion Nacional de Dermatologia
Principal Investigator: Ernesto Rojas, MD Universidad Mayor de San Simón
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Fundacion Nacional de Dermatologia
ClinicalTrials.gov Identifier: NCT01300975     History of Changes
Other Study ID Numbers: ABF-BO-2010-101
First Posted: February 23, 2011    Key Record Dates
Last Update Posted: July 6, 2012
Last Verified: July 2012

Keywords provided by Fundacion Nacional de Dermatologia:
intralesional antimony

Additional relevant MeSH terms:
Leishmaniasis, Cutaneous
Euglenozoa Infections
Protozoan Infections
Parasitic Diseases
Skin Diseases, Parasitic
Skin Diseases, Infectious
Skin Diseases